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Abstract Little is known about the manipulation of IL-17
producing CD4+ T cells (TH17) on a per-cell basis in
humans in vivo. Previous studies on the effects of IL-2 on
IL-17 secretion in non-HIV models have shown divergent
results. We hypothesized that IL-2 would mediate changes
in IL-17 levels among recently HIV-1-infected adults
receiving anti-retroviral therapy. We measured cytokine T
cell responses to CD3/CD28, HIV-1 Gag, and CMV pp65
stimulation, and changes in multiple CD4+ T cell subsets.
Those who received IL-2 showed a robust expansion of
naive and total CD4+ T cell counts and T-reg counts.
However, after IL-2 treatment, the frequency of TH17
cells declined, while counts of TH17 cells did not change
due to an expansion of the CD4+ naïve T cell population
(CD27+CD45RA+). Counts of HIV-1 Gag-specific T cells
declined modestly, but CMV pp65 and CD3/CD28
stimulated populations did not change. Hence, in contrast
with recent studies, our results suggest IL-2 is not a potent
in vivo regulator of TH17 cell populations in HIV-1
disease. However, IL-2-mediated T-reg expansions may
selectively reduce responses to certain antigen-specific
populations, such as HIV-1 Gag.
Keywords Human . T cells . HIV-1 . cytokines .
interleukin-2 . interleukin-17 . T-regs . anti-retroviral therapy
Introduction
Interleukin-17 (IL-17) is primarily secreted by CD4+
(TH17) cells and plays an important role in host defense
by inducing and regulating inflammatory responses [1–7].
We and others have shown that, during HIV-1 and SIV
infection, the frequency of TH17 cells decrease in both
peripheral blood and gut associated lymphoid compart-
ments. This depletion appears to be detrimental to the
control of HIV-1/SIV infection [4, 5, 8–13]. In recent
reports, this loss of TH17 cells in the gut mucosa after SIV
or HIV infection may compromise the gut mucosa and lead
to microbial translocation and increased immune activation
[10, 13–15].
Previous studies have evaluated the effects of
interleukin-2 (IL-2) on IL-17 secretion in non-HIV models
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and have shown divergent results associating with either
increases [1] or constraints [16] on production of TH17 cells
[1–3, 16]. IL-2 has been used in conjunction with anti-
retrovirals to increase CD4+ T-cell counts in HIV-1
infection, and is approved in some European countries for
this purpose [17–30]. The effect of IL-2 administration on
TH17 cells in humans in vivo is not known.
IL-2 therapy in combination with ART has been
shown to lead to elevated levels of CD4+ T cell counts
and T-reg populations, and may exert an important
influence on HIV-1 disease progression [30–39]. The
results from two recent studies, the ESPRIT and SILCAAT
trials were conducted to establish the clinical benefit of
IL-2 immunotherapy. These studies suggested that, despite
a substantial and sustained increase in the CD4+ cell
count, as compared with antiretroviral therapy (ART)
alone, IL-2 plus ART therapy yielded no added clinical
benefit in either study [40]. It has been suggested
elsewhere that, while IL-2 treatment does not associate
with the outcome measuring death from any cause, it may
have a beneficial effect on the incidence of opportunistic
infection [41]. In other studies, clinical benefit has been
observed after IL-2 treatment among anti-retroviral naïve
patients [42]. Other groups have observed that IL-2
improved immune responses against HIV-1, evidenced as
decreased viremia, until IL-2 effects tapered off, with IL-2
helping to maintain CD4+ counts during partial treatment
interruption (PTI) studies [43].
We employed the setting of a previously conducted,
randomized IL-2 clinical trial in recently HIV-1-infected
adults receiving ART, to explore IL-2 as a candidate for
the manipulation of IL-17 expression. We also explore
the effects of IL-2 immunotherapy on changes to the
IFN-γ, TNF-α, and IL-2 T-cell response to HIV-1 Gag
and CMV pp65 peptides, and polyclonal stimulation
(CD3/CD28 stimulation). Others have shown that thera-
peutic SIV vaccination in the presence of low-dose IL-2
boosts CD8+ but not CD4+ T cell responses to SIV Gag
in chronically SIV infected macaques [36]. The effect of
IL-2 in HIV-1 infection on the cytotoxic and non-
cytotoxic (CNAR) anti-HIV response has also been
evaluated, and suggests preservation and expansion of
this T cell mediated mechanism of response [30, 44]. In
contrast, others have shown no functional benefit of IL-2
on CTL activity [45], while others have suggested an
expansion of responses [46]. Yu et al. have shown
proliferative responses of HIV-1 and CMV-specific
CD8+ T cells restored by an in vitro addition of IL-2
[47]. Based on prior studies [16], we hypothesized that
IL-2 mediated expansion of T-regs will broadly suppress
inflammatory T cell responses and act as a negative
regulator, lowering counts of IL-17 expressing CD4+
T cells.
Methods
Study Population Specimens were obtained from persons
enrolled in the OPTIONS study of early HIV-1 infection
conducted in a university-based research clinic at the
University of California, San Francisco. Among those
enrolled in OPTIONS, approximately 90% are within
6 months of acquiring HIV-1 infection [48, 49]. All
participants gave written, informed consent using protocols
approved by the Committee on Human Research, Univer-
sity of California, San Francisco.
Study Design This study is derived from a randomized
clinical trial of IL-2 administration to recently HIV-1
infected human adults who had achieved an HIV-1 RNA
level in plasma of <500 copies/ml on a combination anti-
retroviral regimen (one protease inhibitor and/or one
non-nucleoside reverse transcriptase inhibitor, and at
least two nucleoside reverse transcriptase inhibitors) that
was initiated within 6 months or less of HIV-1 antibody
seroconversion. IL-2 was given subcutaneously (7.5
million units, twice daily) for 5 days at 8-week intervals,
with dose adjustments for toxicity. Patients were ran-
domized to receive IL-2 within 4 weeks of achieving an
HIV-1 RNA level <500 copies/ml, or to remain on ART
alone for the next 48 weeks with an option of receiving
IL-2 at the end of this period. This study was approved
by the Committee on Human Research at the University
of California, San Francisco. All study participants
provided written informed consent prior to entering the
study. HIV-1-uninfected controls employed in this study
were acquired from the Stanford University Blood Bank
(Palo Alto, CA, USA).
Samples Peripheral blood was collected by venipuncture
in blood collection tubes with acid-citrate-dextrose
(Vacutainer, BD Diagnostics, Franklin Lakes, NJ, USA).
Peripheral blood mononuclear cells (PBMC) were isolated
from whole blood by Ficoll density gradient centrifugation,
cryopreserved in fetal calf serum containing 10% DMSO,
and stored at the UCSFAIDS specimen bank.
T Cell Responses Thawed and rested PBMC were stimu-
lated with overlapping peptide pools (all 15mers over-
lapping by 11 aa) in the presence of 10 μg/ml Brefeldin A
(Sigma Aldrich) for 18 h at 37°C. Peptide pools were HIV-
1 SF2 GAG (4.8 μg/mL, 127 peptides, SynPep) and CMV
pp65 (4.25 μg/mL, 138 peptides, SynPep). PBMC from
each subject were also stimulated with a combination of
plate bound anti-CD3 (0.3 μg/ml, Zymed) and soluble anti-
CD28 (2.5 μg/mL, BD Pharmingen), and unstimulated cells
were run in parallel as a negative control. Following
stimulation, PBMCs were treated with 2 mmol/L EDTA,
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washed in PBS, stained with AARD as described above,
then fixed and permeabilized by a 10-min incubation in
FACS lyse, and a 10-min incubation in FACS Perm (both
from BD Biosciences) before staining with fluorescently
labeled antibodies: CD3 and CD8 described above, CD4-
PE-Texas Red (Invitrogen), IFN-γ-FITC, IL-2-PE, TNFα-
Alexa Fluor 700 (all BD Bioscience), and IL-17 Alexa
Fluor 647 (eBioscience). Cells were washed, re-suspended
in FACS buffer, stored at 4°C, and run on a customized BD
LSR II within 18 h. We defined a T cell response as a
cytokine response to stimulus after subtraction of back-
ground signal. Any response with less than 100 events was
excluded. A positive response was 0.07% (2 SD higher than
responses of HIV-seronegative subjects) or higher. T cell
counts reported here were derived by multiplying the
fractional size of each T cell subset by the total,
corresponding CD4+ or CD8+ T cell count/uL derived
from clinical practice.
Flow Cytometry All samples were run on a customized
BD LSR II Flow cytometer within 18 h of staining.
Rainbow beads (Spherotec) were used to standardize
instrument settings between runs. At least 300,000
lymphocytes were collected for each sample assayed by
CFC and at least 200,000 lymphocytes collected for
phenotyping assays. Data was compensated and analyzed
by using Flowjo Software (Treestar). The staining and
gating strategy for identification of cytokine responses
and T-reg cells are shown in supplemental Fig. S1. T-
regulatory cell populations were identified as CD3+CD4+
T cells that express CD25 and FoxP3 and lack expression
of CD127 (IL-7 receptor), this population has previously
been identified as suppressive in functional assays in a
number of studies [50, 51].
ELISPOT Assay The ELISPOT assay was used both for the
detection of IFN-γ and IL-17 secreting cells using IFN-γ
(Mabtech, Cincinnati, OH, USA) and IL-17 (eBioscience)
antibody-paired reagents. Procedures for the ELISPOT
analysis were as previously described [52]. In brief,
equivalent antigen concentrations were used for HIV-1
peptides and CMV lysates. The optimal concentrations of
TLR ligands (Invivogen) used were based on titrated
amounts that elicited IFN-γ secretion. We employed
Staphylococcal Enterotoxin B (SEB) at a concentration of
5 μg/ml (Sigma Aldrich). Soluble anti-CD3 (0.5 μg/mL,
clone HIT3α; BD Biosciences) and soluble anti-CD28
(0.5 μg/mL clone 28.2; BD Biosciences) was used as
previously described in the ELISPOT assay [4]. Spot totals
for duplicate wells were averaged, and all spot numbers
were normalized to numbers of IFN-γ spot-forming units
(SFU) per 1×105 PBMCs. Spot values from medium
control wells were subtracted to determine responses to
each peptide. Responses >100 spots/105 PBMCs were
considered as a positive responding population.
Statistical Analysis We tested for IL-2-associated changes
on test variables by applying the sign rank test to test if the
difference between pre- and post-IL-2 administration time
periods within each group differed from zero. We compared
differences in measurements between groups at baseline
and during the post-IL-2 time period with the Wilcoxon
two-sample test. We assessed correlations between contin-
uous variables by use of the Spearman rank correlation test.
Data were manipulated and statistical tests performed in the
SAS System 9.2 for Windows XP. We employed GraphPad/
Prism (La Jolla, CA, USA) to display results from this
study.
Results
Study Population and Description of HAART and IL-2
Therapy
Using HIV-1 as a model to study the effects of IL-2 on IL-
17 production in vivo, we studied 18 participants from a
randomized clinical trial of IL-2 performed at the Univer-
sity of California San Francisco. We restricted selection of
IL-2 treated subjects to those who completed at least five
cycles (out of a possible six) of IL-2 (Table I). All 18 adults
remained on ART for at least 1 year after randomization. Of
these 18 subjects, 11 subjects received IL-2 and are referred
to as “ART + IL-2.” The remaining seven comparison
subjects who received ART therapy only during the study
period are referred to as “ART.” Virologic responses to
ART were excellent among all participants who achieved
and maintained complete virologic suppression for the
duration of the study. We did not observe a viral rebound
effect among those who either did or did not receive IL-2.
We focused on measures at two time points. Visit 1 was
designated at the time when a viral load of less than 500
copies/mL had been achieved on ART, but before IL-2 had
been administered in the ART + IL-2 group, and as
corresponding time in the ART only group. Visit 2 was
approximately 48 weeks later, and represented a time when
at least five cycles of IL-2 therapy had been administered in
the ART + IL-2, and represented a corresponding time on
treatment in the ART alone group.
Characterization of IL-17 Responses
The elicitation of IL-17 by various mutagens is differen-
tially regulated in mouse and human, and the endogenous
factors eliciting IL-17 are poorly characterized [53]. Viral
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peptides fail to elicit IL-17 production but may be elicited
by other microbial pathogens [4, 6, 9, 13, 54, 55]. To
induce consistent IL-17 secretion, we measured the expres-
sion of IL-17 in response to various TLR agonists, bacterial
components, viral antigens, and polyclonal stimulation to
determine the best mitogen to induce reliable IL-17
secretion. We observed robust secretion of IFN-γ in
response to TLR ligands 1–9, anti-CD3/CD28mAb mix-
ture, and SEB from PBMCs or sorted CD4 T cells by an
ELISPOT assay. Little to no secretion of IL-17 was seen in
response to TLR (Toll-like receptor) ligands, viral peptides
(Fig. 1a–d), or candidal antigens. Stimulation with either
SEB or anti-CD3/CD28 mAb mixture elicited consistent
IL-17 secretion (Fig. 1a–d) in overnight cell cultures. This
is in line with our previous results and by others showing
that differentiation by cytokine polarizing IL-17 induction
or pathogens all appear to rely on prior anti-CD3/CD28
elicitation [4, 6, 54, 56]. Due to the restricted TCR
repertoire of SEB, we elicited IL-17 responses by CD3/
CD28 stimulation. We selected this stimulation for consis-
tency not by use of bacterial or fungal stimuli, whose
presence in the periphery during early infection may be
very low. Furthermore, consistent with prior reports [4, 5,
10, 13], IL-17 levels were lower in HIV-infected subjects
compared to healthy subjects (Fig. 1a).
Baseline T Cell Responses to Stimuli at Visit 1 (Prior to
IL-2 on Both Randomized Populations) We observed that
the magnitude of T cell response cell counts at visit 1 (pre
IL-2 trial period) in response to CD3/CD28, HIV-1 Gag,
and CMV pp65 peptide pools in the two patient populations
did not differ. Thus, the patient groups intended to
subsequently receive IL-2 and not receive IL-2 did not
differ from one another at baseline and, hence, show
evidence the groups were well randomized (Table I).
We observed that IL-17 responses were not induced by
viral peptide pool stimulation of T cells in either CD4+ or
CD8+ T cells, but were induced by TCR (anti-CD3/CD28)
cross-linking in both groups by CD4+ T cells and did not
differ between the two groups (Fig. 2).
Changes in the CD4 T Cell Subsets with or without IL-2
Therapy at Visit 2
For those who received ART+IL-2, CD4+ T cell counts
increased a median of 1,117 cells/uL (interquartile range
(IQR) (672, 1775)) from baseline but showed much more
limited increases in those who received ART alone
(median +123 cells/ul (IQR 0, 366)) (Table I, Fig. 3a).
CD8+ T cell counts did not increase from baseline for
either group (p=0.28 for ART+IL-2 group and p=0.44 for
ART only group). Frequencies and counts of T-reg cells
increased significantly among those who received IL-2,
but did not change among those who did not receive IL-2
(Fig. 3b, c). The expanded T-reg cells were primarily of a
Table I Demographic, Clinical, and Laboratory Measures at Study Entry All Patients on Suppressive ART, but Prior to Receipt of Study Drug
Measurement All Subjects ART Only Arm ART + Il-2 Arm P = b
Median (IQR) Median (IQR) Median (IQR)
N 18 7 11
CD4+T cell count (cells/mL) 630 (525, 810) 630 (432, 810) 630 (525, 817) 0.7
Viral Load (log10 c/mL) 2.3 (2.3, 2.3) 2.3 (2.3, 2.3) 2.3 (2.3, 2.3) 1.0
CD8+ T Cell Activation (% CD38, HLA-DR) 22.5 (15.9, 28.9) 21.2 (17.2, 30.5) 23.7 (14.1, 28.9) 0.7
Age at Study Entry (Years) 34 (29.3, 39.8) 39.4 (31.8, 39.8) 32.4 (28.2, 44.4) 0.7
Time From Cohort Entry (Days) 102 (75, 133) 105 (98, 133) 95 (69, 164) 0.5
Time on Anti-Retroviral Treatment (Days) 84 (56, 97) 84 (83, 87) 82 (49, 150) 0.8
Number (Percent)
Ethnicity
White 17 (94%) 0.4
Asian 1 (6%)
Hispanicc 1 (6%)
Male Gender 18 (100%) NA
Treatment (ART) is defined as at least two nucleoside reverse transcriptase inhibitors, and either one protease inhibitor (PI), one non-nucleoside
reverse transcriptase inhibitor (nnRTI), or both a PI and a nnRTI. This was a first anti-retroviral regimen
a Study entry is the time at which individuals were randomized to either receive or not receive IL-2. This randomization occurred after individuals
demonstrated complete virologic response to ART within 6 months of starting therapy
b Difference between study groups at first study time-point (Wilcoxon 2 sample test or Fisher's exact)
c May be any race
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Fig. 1 Detection of IL-17 secretion and Flow gating strategy to
identify CD4+ and CD8+ Cytokine T cell responses. a Elipsot assay
for TLR stimulation HIV-1 uninfected (n=4) and 2 HIV-1infected
subjects on IL-2 and 2 subjects without IL-2 (n=4). b Gating strategy
for identification of cytokine elicited T cell responses and of T
regulatory cell subsets. a−d Plots show PBMCs from a representative
HIV-1 infected subject. (See Table I). a−c Intracellular detection of
IL-17, IFN-γ, TNF-α, and IL-2 cytokine production elicited by either
anti-CD3/CD28 mAb, Gag, or Pp65 peptide pool stimulation by b
CD4+ and c CD8+ T cell subsets. Arrowheads indicated the gated
population subsequently analyzed. Fluorescence minus one (FMO)
samples were used to define the gates used
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naïve phenotype (FOXP3+CD45RA+ cells) (Sup Figure 1A;
Sup Methods). We further examined maturation markers
(CD27, CD28, CD45RA) (Sup Methods) on total CD4+ and
CD8+ T cells before and after IL-2 administration. We found
that the ART+IL-2 treated group experienced a significant
and large increase in the frequency of naïve (CD27+
CD28+CD45RA+) CD4+ T cell pool (+10 percentage points
from visit 1, p<0.01 (Fig. 3d), and experienced a trend
towards increase in the naïve CD8+ T cell pool (+5
percentage points from visit 1, p=0.08). To better assess
the effects of IL-2 therapy on IL-17 T cell response counts,
we analyzed the change in counts from visit 1 (pre-IL-2) to
visit 2 (post-IL-2). By examining the degree of change, and
not absolute magnitude of change, we aimed to better control
for individual variations in baseline responses.
Changes in the TH17 Cell Responses with or without IL-2
Therapy at Visit 2
We next measured changes in frequency and counts of cells
expressing IL-17 in response to anti-CD3/CD28 stimulation
(T cells responding to this stimuli may be of any specificity)
(Figs. 4 and 5). Among those who received ART+IL-2,
we found that responding IL-17 CD4+ T cells, as well as
IFN-γ, IL-2, and TNF-α, CD4+ T cell responses declined
in frequency from visit 1 to visit 2 among those who
received ART+IL-2 (Fig. 4), but not for those who received
ART alone. CD8+ T cell IFN-γ, TNF-α and polyclonal
responses to CD3/CD28 also declined in frequency, but
only among the ART + IL-2 group (Fig. 4).
We next examined changes in CD4+ and CD8+ T cell
counts in response to CD3/CD28. In contrast to the decline
in frequency of T cell responses to CD3/CD28 in the IL-2-
treated group, we found no change in the count of either
polyfunctional T cells or T cells that expressed only either
IL-17 or IFN-γ (Fig. 5). However, among the ART+IL-2
group, the counts of CD4+ (but not CD8+) T cells that
expressed IL-2 or TNF-α increased significantly from
baseline for the ART+IL-2 group (Fig. 5). That the
frequency of CD3/CD28 responses declined, while absolute
counts either did not decline or in fact increased, may be
explained by an expansion of naïve CD4+ and CD8+ T cell
populations following IL-2 administration (Fig. 3d for
CD4+ data), cell populations that may be unresponsive or
only partially responsive to stimuli, as is discussed below.
Changes in HIV Gag Specific and not CMV pp65 CD4+
and CD8+ T Cell Responses with or without IL-2 Therapy
In Fig. 6a, we observe that ART+IL-2 participants showed
significant decreases in the counts of Gag-specific CD8+ T
Cells expressing IFN-γ and TNF-α compared with base-
line. In addition, polyfunctional Gag-specific T cells (CD8+
IFNγ+IL2+TNFα T cells and CD4+ and CD8+
IFNγ+TNFα+ T cells) declined from baseline in these
participants (Fig. 6a). The frequencies of CD4+ and CD8+
T cell responses to HIV-1 Gag declined for those who
received IL-2 but not for those who received ART alone.
The changes are modest in absolute counts, but as these cell
responses typically make up only a small faction of total T
cell pools, even these modest declines in counts are likely
biologically relevant.
Consistent with prior reports, we found little expression
of IL-17 levels in either HIV-1 Gag-specific CD4+ or
CD8+ T cells [4] (Fig. 6a). Among those who received
ART+IL-2, we observed general agreement between
Fig. 2 Counts of T-cell IL-17
responses to CD3/CD28 and
antigen-specific stimulation. On
the left-hand side are baseline
(visit 1) responses among those
who subsequently received ART
only (green) and on the right-
hand side are responses of those
who subsequently received
ART+IL-2 (orange). Only CD3/
CD28 stimulation of CD4+ T
cells elicited an IL-17 response,
and the magnitude of CD4+
IL-17 response to CD3/CD28
did not differ by study group
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changes in frequencies and changes in counts for HIV-1
Gag CD4+ or CD8+ T cell responses. In contrast to HIV-1
Gag-specific T cell responses (Fig. 6a), and consistent with
findings for CD3/CD28 stimulated T cells (Fig. 4), we
found that counts of CMV pp65-specific CD4+ and CD8+
T cells did not change (Fig. 6b) among those who received
ART+IL-2. The frequencies of CMV pp65-specific CD4+,
but not CD8+ T cell responses, declined for those who
received ART+IL-2 but not for those who received ART
alone.
Relationship of Change in T-reg Frequencies to Change
in T Cell Responses to HIV-1 Gag Among Those Who
Received ART and IL-2
We observed (Fig. 7) that an increase in T-reg frequency
attributable to IL-2 use, among the ART + IL-2 treated
group, was associated with declines in IFN-γ, TNF-α CD4
+ T cell responses to HIV-1 Gag, tended to associate with
IL-2 responses to Gag, but did not associate with changes
in IL-17 responses to Gag (p=0.9)
Fig. 3 Changes in CD4+ T cell
counts, T-reg cell frequency,
and counts in naïve CD4+ T cell
counts (maturation profile). P
values are the results of sign
rank tests comparing visit 1 to
visit 2 values (a). The first row
shows pre- (visit 1) and post-
IL-2 (visit 2) study period total
CD4+ T cell counts for those
who did not receive IL-2 (green)
and those who did receive IL-2
(orange) (b). The second row
shows pre- (visit 1) and
post-IL-2 (visit 2) study period
T-regulatory percentages for
those who did not receive IL-2
(green) and those who did
receive IL-2 (orange) (c). The
third row shows pre- (visit 1)
and post-IL-2 (visit 2) study
period T-regulatory counts for
those who did not receive IL-2
(green) and those who did
receive IL-2 (orange) (d) Naïve
4s increase significantly in pro-
portion (p<0.005) for the
ART+IL-2 group. There was no
change in the ART only group in
naïve T cell populations by
frequency or counts
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Discussion
We observed that administration of IL-2 resulted in no
change in the numbers of peripheral blood TH17 cells [1–3,
16]. IL-2 administration during ART leads to increases in
total CD4+ T cell and T-reg populations. Among those who
received IL-2, the bulk of the increase in the CD4+ T cell
population appeared to be attributable to an expansion of
naïve CD4+ T cells (CD27+/CD45A+). Hence, while TH17
counts after IL-2 did not change, IL-2 recipients did
experience a decline in the frequency of TH17 responses
to CD3/CD28. This effect was likely due to an increase of
naïve CD4+ T and CD8+ cells that were not responsive to
stimuli, diluting the frequency of TH17 cells. Previous
reports have suggested IL-2, which expands T-reg popula-
tions, may limit IL-17 CD4+ populations [16] in a STAT5-
dependent manner, which is consistent with our findings.
Indeed, taken together, our data suggest IL-2 limits
Fig. 5 Change in counts of CD3/CD28 responding T cells after
ART+IL-2 (a). The data shown are the change from in count from visit
1 to visit 2 counts (calculated as visit 2 values minus visit 1 values). On
the left-hand side are changes in counts of CD4+ T cell responses to
CD3/CD28 stimulation, and on the right-hand side are CD8+ T cell
responses to CD3/CD28 stimulation. The ART-only group is shown in
green, the group that received ART+IL-2 is shown in orange. In
contrast to frequencies, the counts of CD4+ and CD8+ T cell
responses to CD3/CD28 stimulation were not observed to decrease
after IL-2 treatment (ART+IL-2, orange) for multiple cytokine response
categories (asterisks, p<0.05 by sign rank test (change from baseline))
Fig. 4 Change in frequencies of CD3/CD28 responding T cells after
ART+IL-2: On the left-hand side of Fig. 5 are changes in frequency of
CD4+ T cell responses to CD3/CD28 stimulation, and on the right-
hand side are CD8+ T cell responses to CD3/CD28 stimulation. The
ART-only group is shown in green, the group that received ART+IL-2
is shown in orange. The frequency of CD4+ and CD8+ T cell
responses to CD3/CD28 stimulation were observed to significantly
decrease after IL-2 treatment (ART+IL-2, orange) for multiple
cytokine response categories. Asterisks, p<0.05 by sign rank test
(change from baseline)
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Fig. 6 Decline in counts of Gag responsive T cells for ART+IL-2 and
no change in pp65 responding. Data shown is the difference between
counts of a HIV-1 Gag and b CMV pp65, T cell responses between
pre and post IL-2 treatment (visit 2 counts minus visit 1 counts). On
the left-hand side of Fig. 5 are changes in counts of CD4+ T cell
responses to Gag or CMV peptide stimulation, and on the right-hand
side are CD8+ T cell responses to Gag or CMV peptide stimulation
(asterisks, p<0.05 by sign rank test (change from baseline)). More
detail may be found in supplementary Fig. 2
Fig. 7 Relationship of Change
in CD4+ T cell cytokine
responses to HIV-1 Gag stimu-
lation to change in the frequency
of T-reg cells. Change was
calculated from pre to post-IL-2
treatment, among the IL-2
treated group only. Correlations
are Spearman rank tests. An
increase in T-reg frequency was
associated with decreases
in IFN-γ, IL-2, and TNF-α
responses, but not IL-17
responses
J Clin Immunol (2010) 30:681–692 689
production of—but does not reverse—IL-17 expression in
CD4+ T cells in humans.
Among those who received ART and IL-2, we observed
modest but significant decreases in counts of CD4+ and
CD8+ T cell responses to HIV-1 Gag. Responses to CD3/
CD28 and CMV pp65 stimuli did not change. An
expansion of naïve CD4+ and CD8+ T cells appears to
have diluted the frequency of T cells responding to CD3/
CD28 and CMV pp65 stimuli among the IL-2 recipients.
Our findings indicate that the administration of IL-2, and
expansion of T-reg populations, was associated with
reduction of select T cell responses, such as suppression
of HIV-1 Gag responses, while failing to suppress T cell
responses of other specificities, such as CMV pp65. This
suppressive activity may have been dependent on the
functional profile of the Gag response, rather than upon
an antigen-specific T-regulatory response. HIV-1-specific T
cell responses have fewer polyfunctional (IFN-γ/TNF-α)
CD8+ T cells, being dominated by IFN-γ responses. The
IL-2 expanded T-reg population may have selectively
targeted mono-functional T cell responses to Gag—that is
cell populations expressing only one cytokine, such as
IFN-γ. The specific characteristics of individual antigen-
specific populations may render themselves targets for T-
reg suppressive activity, perhaps by “adaptive” T-regs
produced in the periphery and in response to infection.
“Adaptive” T-regs are a population of T-regs that may be
derived from the total CD4+ T cell pool by a cytokine such
as TGF-β or IL-2, and act to suppress and regulate antigen
specific T cell responses during infection [57]. Selective
reduction of monofunctional T cell populations by T-regs
may ensure balanced expression of cytokines of varying
action at the local tissue level.
Our observation of an IL-2-mediated expansion of a
naïve CD4+ T cell population that does not mount an IFN-
γ response to polyclonal stimulation is consistent with prior
reports by Sereti et al. [60]. We extend these findings by
suggesting that IL-2 may expand a population of CD8+ T
cells that do not respond to CD3/CD28 stimulation, nor to
antigen-specific stimuli. That said, in contrast to IFN-γ and
IL-17 responses, the absolute count of CD3/CD28-stimu-
lated CD4+ T cells expressing IL-2 and TNF-α increased
significantly from baseline in IL-2-treated participants. The
increase in IL-2 may be explained as an effect of up-
regulation of IL-2 production secondary to exogenous IL-2
administration and stimulation through CD25, the IL-2
receptor. Expanded T-reg populations may have broadly
suppressed production of new monofunctional IFN-γ
responses among the polyclonal CD3/CD28 responding
population, holding that population constant in number,
similar to the effect observed for HIV-1 Gag IFN-γ responses.
Two recent studies highlight the role of IFN-γ in control
of T-regulatory cell activity and type-1 T cell responses [58,
59] in auto-immune models. Some have suggested that IL-
17 may be negatively regulated by inflammatory cytokines
present during HIV-1 infection, such as IFN-γ [61]. We
observed that the IL-2-mediated expansion of T-regs did
associate with a reduction in the IFN-γ response to HIV-1
Gag stimulation. Therefore, it bears mention that manipu-
lation of IFN-γ via the effects of IL-2 might independently
or synergistically modulate select T-regulatory cell subsets.
However, in our study, we did not observe a general or
broad decline in T cell IFN-γ expression, nor of TH17
counts, across stimuli, among IL-2-treated persons.
Alternative strategies to the manipulation of IL-17 levels
in humans, including the evaluation of IL-1β, IL-23, and
IL-6 [62], may be required. That said, the failure of IL-2 to
expand IL-17 producing CD4+ T cells while increasing
T-reg populations may augur well for IL-2 use in auto-
immunity, diseases characterized by depleted T-reg pop-
ulations, and elevated IL-17 expression. To achieve
expanded T-reg counts and function, as well as increased
CD4+ T cell IL-17 expression, might require IL-2 and the
added manipulation of ROR-γt [55], IL-6, IL-23, and/or
TGF-β.
As most participants continued on an anti-retroviral
regimen after the IL-2 trial had been concluded, our study
could not determine if IL-2-mediated expansion of T-regs,
and the associated reductions in monofunctional IFN-γ
expressing Gag T cell responses, will confer any long-term
clinical benefit for these persons once they halt treatment.
That said, newly expanded T-reg cells may allow suppres-
sion of inflammatory T cell responses, such as those to
HIV-1 Gag. These Gag responses are narrow in function,
may be ineffective or harmful to the host, perhaps via
exaggerated IFN-γ levels, in turn suppressing IL-17 and
disabling responses to infection [61]. That IL-17 producing
CD4 + T cell populations, which may be beneficial in HIV-
1 disease, were not expanded may offset the benefit of a
restored T-reg population. Further human trials of the
effects on IL-2 on T-reg suppression of select T cell
responses, such as IFN-γ and the factors which may
expand IL-17 production, may reveal the appropriate
balance and function of these regulatory T cell populations
in infection and healthy adults.
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